You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

hypomethylating agents

Showing 1 - 25 of 5,358
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia, MDS Trial (Cladribine, Cytarabine, Decitabine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • (no location specified)
Mar 1, 2023

Acute Myeloid Leukemia Trial (Tagraxofusp (Cycles 1-2), Azacitidine, Tagraxofusp (Cycles 3-12))

Not yet recruiting
  • Acute Myeloid Leukemia
  • Tagraxofusp (Cycles 1-2)
  • +2 more
  • (no location specified)
Jun 28, 2022

Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome Trial in Houston (Fostamatinib)

Recruiting
  • Refractory Chronic Myelomonocytic Leukemia
  • Refractory Myelodysplastic Syndrome
  • Houston, Texas
    M D Anderson Cancer Center
Aug 31, 2021

MDS Trial in Worldwide (MBG453, Placebo, Hypomethylating agents)

Active, not recruiting
  • Myelodysplastic Syndromes
  • Duarte, California
  • +46 more
Jan 20, 2023

Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial (UAE Inhibitor TAK-243)

Not yet recruiting
  • Myelodysplastic Syndrome
  • +4 more
  • UAE Inhibitor TAK-243
  • (no location specified)
Oct 20, 2022

MDS, Dendritic Cell, Hypomethylating Agents Trial in Beijing (DC vaccine)

Recruiting
  • Myelodysplastic Syndromes
  • +3 more
  • DC vaccine
  • Beijing, China
    Department of hematology
Aug 10, 2021

Unfit AML Patients Treated With Combination Venetoclax Plus

Recruiting
  • Acute Myeloid Leukemia
  • Venetoclax plus HMA
  • Bergamo, Italy
  • +22 more
Oct 10, 2022

Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML

Completed
  • Relapsed Acute Myeloid Leukemia
  • +3 more
  • VAH regimen
  • VEN+HMA regimen
  • Guangzhou, Guangdong, China
    Department of Hematology,Nanfang Hospital, Southern Medical Univ
Jul 8, 2022

Registry on Hypomethylating Agents in Myeloid Neoplasms

Active, not recruiting
  • Chronic Myelomonocytic Leukemia
  • +2 more
  • non interventional
  • Feldkirch, Austria
  • +19 more
Jul 20, 2021

Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute

Recruiting
  • Acute Myeloid Leukemia, Adult
  • +2 more
  • Trieste, Italy
    SC Ematologia Ospedale Maggiore
Sep 14, 2020

Hypomethylating Agents in Acute Myeloid Leukemia

Unknown status
  • Acute Myeloid Leukemia
  • Immunogenic profile
  • Brescia, BS, Italy
  • +13 more
Feb 25, 2021

Myelodysplastic Syndrome (MDS) Trial in United States (MBG453, Azacitidine, Decitabine)

Recruiting
  • Myelodysplastic Syndrome (MDS)
  • Chandler, Arizona
  • +22 more
Dec 5, 2022

MDS Trial in United States (Pracinostat, Azacitidine)

Terminated
Has Results
  • Myelodysplastic Syndromes
  • Duarte, California
  • +24 more
Feb 4, 2022

Hypomethylating Agent, Venetoclax, Myeloid Malignancy Trial in Shanghai (Venetoclax, Azacitidine or decitabine)

Recruiting
  • Hypomethylating Agent
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Jiao Tong University School of Medicine Affilated Shang
May 2, 2023

Acute Myeloid Leukemia Trial in Worldwide (MBG453, Venetoclax, Azacitidine)

Active, not recruiting
  • Acute Myeloid Leukemia
  • Birmingham, Alabama
  • +27 more
Jan 20, 2023

Intervention Trial in Rochester (GO-EXCAP Mobile App)

Completed
  • Intervention
  • GO-EXCAP Mobile App
  • Rochester, New York
    University of Rochester Medical Center
Dec 7, 2021

Acute Myeloid Leukemia, MDS Trial in Cleveland

Unknown status
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
    • Cleveland, Ohio
      Cleveland Clinic
    Apr 9, 2019

    MDS/MPN Trial in Nanjing (Azacitidine (AZA) with Ruxolitinib)

    Recruiting
    • MDS/MPN
    • Azacitidine (AZA) with Ruxolitinib
    • Nanjing, Jiangsu, China
      The First Affiliated Hospital of Nanjing Medical University
    Apr 17, 2023

    Ovarian Cancer Trial in Maywood (Decitabine, Carboplatin, Paclitaxel)

    Not yet recruiting
    • Ovarian Cancer
    • Maywood, Illinois
      Loyola University Medical Center
    Aug 1, 2023

    MDS Trial run by the National Cancer Institute (NCI) (KPT-8602, Inqovi)

    Not yet recruiting
    • Myelodysplastic Syndromes
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jun 30, 2023

    Myeloid Malignancy, Acute Myeloid Leukemia Trial in Cleveland (Venetoclax, Decitabine)

    Not yet recruiting
    • Myeloid Malignancy
    • Acute Myeloid Leukemia
    • Cleveland, Ohio
      University Hospitals Seidman Cancer, Case Comprehensive Cancer C
    Nov 8, 2023

    Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome, Low-risk Myelodysplastic Syndrome Trial in France, Germany,

    Completed
    • Acute Myeloid Leukemia
    • +2 more
    • Nantes, Nantes Cedex 1, France
    • +7 more
    Dec 20, 2021

    MDS, Progressive Disease Trial in Buffalo, Winston-Salem (CPI-613, Hydroxychloroquine)

    Withdrawn
    • Myelodysplastic Syndromes
    • Progressive Disease
    • Buffalo, New York
    • +1 more
    Apr 8, 2021

    AML Trial in Berne (Image-based ex-vivo drug screening platform (pharmacoscopy))

    Recruiting
    • AML
    • Image-based ex-vivo drug screening platform (pharmacoscopy)
    • Berne, Switzerland
      Departement of Medical Oncology, University Hospital Berne
    Feb 8, 2023

    Acute Myeloid Leukemia Trial in Germany (Venetoclax plus Azacitidine, standard of care chemo plus gemtuzumab ozogamicin)

    Not yet recruiting
    • Acute Myeloid Leukemia
    • Venetoclax plus Azacitidine
    • standard of care chemotherapy plus gemtuzumab ozogamicin
    • Essen, NRW, Germany
    • +17 more
    Jun 6, 2023